7月23日，由新疆金融投资集团(以下简称：新疆金投)主办、德展健康（000813）承办的"新疆药物研发 创新及行业交流研讨会"在乌鲁木齐落下帷幕，汇聚政府部门、金融机构、教育行业、科技行业和医药 行业代表共同探讨新疆医药创新发展方向。中国工程院院士杨宝峰教授、韩德民教授受邀参加此次会 议。 资料显示，德展健康主要从事心脑血管药物的研发、生产和销售，是国产降血脂药龙头企业，曾连续八 年蝉联中国制药工业百强，主导起草制定了多项国家药品质量标准，曾荣获"国家科学技术进步二等 奖"。公司专注心脑血管、神经系统、抗肿瘤等重大医学领域攻关，药物研发管线涵盖化学药、生物药 及DNA核酸药一类创新药等。 目前，德展健康已建立完善的研发体系，建有四大专业医药研发平台、博士后工作站、院士工作站，并 与多所知名高校、科研院所达成技术与人才合作。正积极推进多个创新药项目，包括神经保护剂 WYY、抗血栓ZT、大麻二酚(CBD)相关药物等。 科研是医药研发企业永恒不变的核心竞争力，2024年底，德展健康公告与中国工程院杨宝峰院士签署了 《合作框架协议》，双方共同在心脑血管、肿瘤、代谢系统疾病、肺动脉高压、神经和精神类等多种领 域药品及保 ...

Group 1 - The establishment of the academician expert workstation at Deyizhi Pharmaceutical Co., Ltd. is approved by the Beijing Association for Science and Technology, marking a significant step in the company's innovation-driven development strategy [1] - The collaboration with Academician Yang Baofeng will focus on drug research and development in various fields, including cardiovascular diseases, tumors, metabolic system diseases, pulmonary hypertension, and neurological disorders [1][2] - Deyizhi Health is actively advancing several innovative drug projects, including neuroprotective agents, antithrombotic drugs, and cannabinoid-related medications [2] Group 2 - The partnership with Academician Yang Baofeng's team is expected to enhance the company's technological capabilities and innovation strategies, leading to the development of competitive new products and processes [2] - The approval of the academician expert workstation is seen as a crucial move to improve the company's research capabilities, attract high-end talent, and promote the transformation of research results [3] - The company aims to strengthen existing innovation platforms, enhance technological innovation capabilities, and accelerate the industrialization of research achievements to drive revenue growth and diversify its business structure [3]